ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ERLEADA
Prostate and other male cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ERLEADA Rx

Generic Name and Formulations:
Apalutamide 60mg; tabs.

Company:
Janssen Biotech, Inc.

Therapeutic Use:

RECENT UPDATES

Monograph added.

Indications for ERLEADA:

Treatment of non-metastatic, castration-resistant prostate cancer.

Adult:

Swallow whole. 240mg once daily. Give concurrent gonadotropin-releasing hormone (GnRH) analog or patient should have had bilateral orchiectomy.

Children:

Not established.

Contraindications:

Pregnancy.

Warnings/Precautions:

Permanently discontinue if seizure occurs. Evaluate for fracture and fall risk. Withhold dose if Grade ≥3 toxicity or intolerable side effect occurs; resume at same or reduced dose if improved to Grade ≤1 or original grade. Embryo-fetal toxicity. Female partners of reproductive potential: use effective contraception during and for 3 months after last dose.

Interactions:

Potentiated by strong CYP2C8 or CYP3A4 inhibitors; reduce dose based on tolerability. Antagonizes drugs metabolized by CYP3A4, CYP2C19, or CYP2C9; use alternatives when possible. Caution with concomitant P-gp, BCRP, OATP1B1, or UGT substrates.

Pharmacological Class:

Androgen receptor inhibitor.

Adverse Reactions:

Fatigue, hypertension, rash, diarrhea, nausea, weight loss, arthralgia, fall, hot flush, decreased appetite, fracture, peripheral edema; seizure, infertility.

Generic Availability:

NO

How Supplied:

Tabs—120

Sign Up for Free e-newsletters



CME Focus